Breas Medical Initiates Vivo 45 LS Ventilator Correction

The company enacted the recall after identifying the potential for short term elevated levels of formaldehyde exposure to users under specific conditions.

Katie Hobbins, Managing Editor

August 12, 2024

2 Min Read
Vivo 45 LS Ventilator
Image courtesy of Breas Medical

Breas Medical recently initiated a voluntary recall of its Vivo 45 LS ventilators after identifying the potential for elevated toxic chemical exposure under specific conditions. The recall is considered a correction, not product removal and affects 8,186 ventilators distributed from Feb. 12, 2021, to July 24, 2024.

The company notified customers in the US by email and phone that internal testing of Vivo 45 LS indicated the potential for short term elevated levels of formaldehyde exposure to users under specific circumstances.

"The test conditions represent operation under certain conditions, beyond those expected to be encountered during actual operation of the device with patients," a representative from Breas told MD+DI. "We are communicating with our customers to ensure that the correction is notified and no patient treatment is disrupted."

Exposure to short term formaldehyde emissions could result in adverse pulmonary or neurological effects like the potential for transient, reversible airway irritation or inflammation that could lead to “airway hyperresponsiveness such as asthma in small pediatric patients resulting in additional medical intervention (e.g., bronchodilator administration, adjustment of ventilator settings, increased duration or degree of ventilatory support and/or oxygen support),” according to the company press release.

Currently, Breas has not received any reports of patient injury or adverse effects related to the correction.

Affected devices can be identified by the model name on the front panel of the product and the model and serial numbers on the back panel.

As part of the correction, the company is notifying distributors and commercial customers about updates to the device’s instructions for use (IFU). The changes to the IFU include reducing the maximum room air temperature for operation of the device from 104°F (40°C) to 86°F (30°C) and requiring new devices shipped through July 24, 2024, to be pre-run for 14 days prior to patient use.

“End users and other recipients of the Vivo 45 LS device in the US should contact the company that provided the device or Breas Medical for further information regarding the necessary corrective measures if needed,” Breas said in the correction announcement.

The company is still evaluating the root cause for the issue.

"Breas is continuing its evaluation, including identifying and eliminating the root cause of formaldehyde emissions," the company told MD+DI.

About the Author

Katie Hobbins

Managing Editor, MD+DI

Katie Hobbins is managing editor for MD+DI and joined the team in July 2022. She boasts multiple previous editorial roles in print and multimedia medical journalism, including dermatology, medical aesthetics, and pediatric medicine. She graduated from Cleveland State University in 2018 with a bachelor's degree in journalism and promotional communications. She enjoys yoga, hand embroidery, and anything DIY. You can reach her at [email protected].

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like